The rationale for abandoning sickle trait screening of red blood cell units for patients with sickle cell disease
John Aneke(University Health Network), Christine Cserti‐Gazdewich, David Barth(University Health Network), Kevin H.M. Kuo(University Health Network), Jacob Pendergrast, Richard Ward(University of Tennessee Health Science Center)
Cited by 7
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162